Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET

Company Participants

Ran Meir - Head, Investor Relations
Richard Francis - Chief Executive Officer
Eric Hughes - Head, R&D & Chief Medical Officer
Eli Kalif - Chief Financial Officer

Conference Call Participants

Umer Raffat - Evercore ISI
David Amsellem - Piper Sandler
Ash Verma - UBS
Balaji Prasad - Barclays
Jason Gerberry - Bank of America
Yifeng Liu - HSBC
Thibault Boutherin - Morgan Stanley
Chris Schott - JPMorgan
Glen Santangelo - Jefferies

Operator

Hello, and welcome to the First Quarter 2024 Teva Pharmaceuticals Industries Limited Earnings Conference Call. My name is Alex. I'll be coordinating the call today. [Operator Instructions]

I'll now hand it over to your host, Ran Meir, Head of Investor Relations. Please go ahead.

Ran Meir

Thank you Alex, and thank you everyone for joining us today.

We hope you have had a chance to review our Q1 results press release along with the press release announcing positive Phase 3 results from olanzapine LAI trial, both issued earlier this morning. Copies of these press releases, along with the slides presented during this call, are available on our website at ir.tevapharm.com.

Please review our forward-looking statements on Slide #2. Additional information on these statements and our non-GAAP financial measures can be found on our earnings release and in our SEC forms 10-K and 10-Q.

To begin today's call, Richard Francis, Teva's CEO, will provide an overview of Teva's first quarter results and business performance, recent events, and our focus and priorities going forward; then, Dr. Eric Hughes, our Head of R&D and Chief Medical Officer, will discuss progress on our innovative pipeline; our CFO, Eli Kalif, will follow up by reviewing the first quarter financial results in more detail.

Please note that today's call will run approximately one hour.

And with that, I will turn the call over to Richard. Richard, if you would, please.

Richard Francis

Thank you, Ran, and good morning, everybody. I'm glad you could join us this morning.

I'm excited to talk to you about our results for Q1 2024. Just to remind you it's a year today almost since we launched the Pivot to Growth strategy, a strategy designed to get Teva back to growth and I'm pleased to say that this is our fourth quarter in a row of continuous growth. So, the strategy is clearly having some effect and I'll go into a bit of detail as to why that is and what's driving it.